Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Tacrolimus and Methotrexate for GVHD Prevention
NCT00369226Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2006
- Primary completion
- Jul 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximally Tolerated Dose of Bortezomib at 45 days, Successful Initial Engraftment at 45 days and 1 more. Started Aug 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00369226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369226.